In this GLP-1 round up: Oral GLP-1 delivers up to 12.4% weight loss in Phase III trial, offering injection-free alternative High-dose semaglutide achieves 25%+ weight loss in one-third of patients without added safety concerns FDA provides regulatory clarity for muscle-preserving drugs to break through the weight loss plateau WHO issues first recommendation for GLP-1s in obesity, framing it as chronic disease requiring long-term treatment Table of Contents New Drug Formulations and Clinical Trial Data Orforglipron: Phase III Data for Oral GLP-1 Eli Lillys orforglipron, an oral GLP-1 receptor agonist, reported Phase III results from the ATTAIN-1 trial in the New England Journal of Medicine
It also has appetite-suppressing effects, making it a valuable adjunct for patients who need additional metabolic support
Esse movimento deve intensificar a concorrncia nos prximos anos
Plus, Baker suspects that broader availability of GLP-1 medications through Hims & Hers and similar platforms such as Ro will drive down prices long-term, and may spur cost-offsetting programs to spring up to help meet demand
So, I think the markets are, as you can expect, not going to fully price in everything that the Fed is suggesting
